Transaction in Own Shares • Dec 16, 2025
Transaction in Own Shares
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information ![]()
RNS Number : 6381L
EKF Diagnostics Holdings PLC
16 December 2025
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Executive Chair share purchase
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that on Monday 15 December, Julain Baines, Executive Chair, purchased a total of 85,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 23.0 pence per Ordinary Share.
Following this transaction, Julian Baines' total interest in the Company is 1,751,288 Ordinary Shares, representing approximately 0.40% of the total voting rights over the Company's issued share capital.
The Notification of Dealing Form required in accordance with UK MAR is set out below as is the Standard form for notification of major holdings received by EKF today.
| EKF Diagnostics Holdings plc | www.ekfdiagnostics.com | ||
| Julian Baines, Executive Chair | Via Walbrook PR | ||
| Gavin Jones, Chief Executive Officer | |||
| Tel: +44 (0)20 7496 3000 | |||
| Singer Capital Markets (Nominated Adviser & Broker) | |||
| Phil Davies / Oliver Platts | |||
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or [email protected] | ||
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | ||

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global diagnostics business focussed on:
· Point-of-Care analysers in the key areas of Hematology and Diabetes.
· Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications.
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Julian Baines | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Chair | |||
| b) | Initial notification /Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | EKF Diagnostics Holdings plc | |||
| b) | LEI | 213800DXTF3EAUK1AR05 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 1 pence each | |||
| Identification code | GB0031509804 | ||||
| b) | Nature of the transaction | Purchase of Ordinary Shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 23p | 85,000 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | N/A single transaction | ||||
| - Price | |||||
| e) | Date of the transaction | 15 December 2025 | |||
| f) | Place of the transaction | London Stock Exchange, AIMX | |||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHUVVVRVOUUAAA
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.